Inhibition of Drug-Induced Apoptosis by Survival Factors in PC12 Cells

Abstract: Pheochromocytoma (PC12) cells have been shown to undergo apoptosis (programmed cell death) when deprived of serum and to be rescued by nerve growth factor, fibroblast growth factor, dibutyryl cyclic AMP, aurintricarboxylic acid, or exogenous expression of bcl-2 . We show here that the cytotoxic drugs cycloheximide, actinomycin D, colchicine, and EGTA also induce apoptosis in PC12 cells. These findings prompted us to investigate whether apoptosis induced by these drugs involves similar pathways in each case, and whether the factors preventing the apoptotic death of serum-deprived PC12 cells can also protect the cells from apoptosis induced by the cytotoxic drugs. Nerve growth factor, dibutyryl cyclic AMP, and expression of bcl-2 inhibited apoptosis induced by all four cytotoxic drugs. Fibroblast growth factor inhibited apoptosis induced by EGTA or colchicine. Aurintricarboxylic acid inhibited apoptosis induced by EGTA. These results suggest that apoptosis induced by treatments with the various drugs is mediated by different initiating pathways, all of which converge into a final, common pathway. Nerve growth factor, dibutyryl cyclic AMP, and bcl-2 appear to affect the final common pathway, whereas fibroblast growth factor and aurincarboxylic acid appear to be more specific and affect only some of the pathways.     

Serum TG-lowering properties of plant sterols and stanols are associated with decreased hepatic VLDL secretion

Plant sterols and stanols are structurally similar to cholesterol and when added to the diet they are able to reduce serum total- and LDL-cholesterol concentrations. They also lower serum triglyceride concentrations in humans, particularly under conditions of hypertriglyceridemia. The aim of this study was to unravel the mechanism by which plant sterols and stanols reduce serum triglyceride concentrations in high-fat diet (HFD) fed mice. Male C57BL/6J mice were fed HFD for 4 weeks. Subsequently, they received HFD, HFD supplemented with 3.1% plant sterol ester (PSE) or HFD supplemented with 3.1% plant stanol ester (PSA) for another three weeks. Both PSE and PSA feeding resulted in decreased plasma triglyceride concentrations compared with HFD, while plasma cholesterol levels were unchanged. Interestingly, hepatic cholesterol levels were decreased in the PSE/PSA groups compared with HFD and no differences were found in hepatic triglyceride levels between groups. To investigate the mechanism underlying the hypotriglyceridemic effects from PSE/PSA feeding, we measured chylomicron and VLDL secretion. PSE and PSA feeding resulted in reduced VLDL secretion, while no differences were found between groups in chylomicron secretion. In conclusion, our data indicate that plasma triglyceride-lowering resulting from PSE and PSA feeding is associated with decreased hepatic VLDL secretion.     

Enhanced HIV-1 neutralization by a CD4-VH3-IgG1 fusion protein

HIV-1 gp120 is an alleged B cell superantigen, binding certain VH3+ human antibodies. We reasoned that a CD4-VH3 fusion protein could possess higher affinity for gp120 and improved HIV-1 inhibitory capacity. To test this we produced several human IgG1 immunoligands harboring VH3. Unlike VH3-IgG1 or VH3-CD4-IgG1, CD4-VH3-IgG1 bound gp120 considerably stronger than CD4-IgG1. CD4-VH3-IgG1 exhibited ≈1.5-2.5-fold increase in neutralization of two T-cell laboratory-adapted strains when compared to CD4-IgG1. CD4-VH3-IgG1 improved neutralization of 7/10 clade B primary isolates or pseudoviruses, exceeding 20-fold for JR-FL and 13-fold for Ba-L. It enhanced neutralization of 4/8 clade C viruses, and had negligible effect on 1/4 clade A pseudoviruses. We attribute this improvement to possible pairing of VH3 with CD4 D1 and stabilization of an Ig Fv-like structure, rather than to superantigen interactions. These novel findings support the current notion that CD4 fusion proteins can act as better HIV-1 entry inhibitors with potential clinical implications.     

The ubiquitously expressed bZIP inhibitor,JDP2, suppresses the transcription of its homologue immediate early gene counterpart,ATF3

JDP2 is a ubiquitously expressed bZIP repressor protein. JDP2 binds TPA response element and cyclic AMP response element located within various promoters. JDP2 displays a high degree of homology to the immediate early gene ATF3. ATF3 plays a crucial role in the cellular adaptive response to multiple stress insults as well as growth stimuli. We have identified ATF3 as a potential target gene for JDP2 repression. JDP2 regulates the ATF3 promoter potentially through binding to both the consensus ATF/CRE site and a non-consensus ATF3 auto-repression DNA-binding element. Expression of ATF3 protein in wild-type mouse embryo fibroblast (MEF) cells is below the detectable levels, whereas, JDP2 disrupted MEF cells display noticeable level of ATF3 protein. Following either serum or ER stress stimulation, ATF3 expression is potentiated in JDP2-KO fibroblast cells as compared with wild-type cells. Mice with either JDP2 over-expression or JDP2 disruption display undetectable level of ATF3 protein. However, ATF3 induction in response to either growth or stress signals is dependent on JDP2 expression level. ATF3 induction is attenuated in JDP2 over-expressing mice whereas is potentiated in JDP2-KO mice as compared with the corresponding wild-type mice. Collectively, the data presented strongly suggest that JDP2 plays a role in the determination of the ATF3 adaptive cellular threshold response to different stress insults and growth stimuli.     

DAP‐kinase‐mediated phosphorylation on the BH3 domain of beclin 1 promotes dissociation of beclin 1 from Bcl‐XL and induction of autophagy

Autophagy, an evolutionarily conserved process, has functions both in cytoprotective and programmed cell death mechanisms. Beclin 1, an essential autophagic protein, was recently identified as a BH3‐domain‐only protein that binds to Bcl‐2 anti‐apoptotic family members. The dissociation of beclin 1 from its Bcl‐2 inhibitors is essential for its autophagic activity, and therefore should be tightly controlled. Here, we show that death‐associated protein kinase (DAPK) regulates this process. The activated form of DAPK triggers autophagy in a beclin‐1‐dependent manner. DAPK phosphorylates beclin 1 on Thr 119 located at a crucial position within its BH3 domain, and thus promotes the dissociation of beclin 1 from Bcl‐X_L and the induction of autophagy. These results reveal a substrate for DAPK that acts as one of the core proteins of the autophagic machinery, and they provide a new phosphorylation‐based mechanism that reduces the interaction of beclin 1 with its inhibitors to activate the autophagic machinery.     

GLTSCR2/PICT-1, a Putative Tumor Suppressor Gene Product,Induces the Nucleolar Targeting of the Kaposi's Sarcoma-Associated Herpesvirus KS-Bcl-2 Protein

KS-Bcl-2, encoded by Kaposi''s sarcoma-associated herpesvirus (KSHV), is a structural and functional homologue of the Bcl-2 family of apoptosis regulators. Like several other Bcl-2 family members, KS-Bcl-2 protects cells from apoptosis and autophagy. Using a yeast two-hybrid screen and coimmunoprecipitation assays, we identified a novel KS-Bcl-2-interacting protein, referred to as protein interacting with carboxyl terminus 1 (PICT-1), encoded by a candidate tumor suppressor gene, GLTSCR2. Confocal laser scanning microscopy revealed nucleolar localization of PICT-1, whereas KS-Bcl-2 was located mostly at the mitochondrial membranes with a small fraction in the nucleoli. Ectopic expression of PICT-1 resulted in a large increase in the nucleolar fraction of KS-Bcl-2, and only a minor fraction remained in the cytoplasm. Furthermore, knockdown of endogenous PICT-1 abolished the nucleolar localization of KS-Bcl-2. However, ectopically expressed PICT-1 did not alter the cellular distribution of human Bcl-2. Subsequent analysis mapped the crucial amino acid sequences of both KS-Bcl-2 and PICT-1 required for their interaction and for KS-Bcl-2 targeting to the nucleolus. Functional studies suggest a correlation between nucleolar targeting of KS-Bcl-2 by PICT-1 and reduction of the antiapoptotic activity of KS-Bcl-2. Thus, these studies demonstrate a cellular mechanism to sequester KS-Bcl-2 from the mitochondria and to downregulate its virally encoded antiapoptotic activity. Additional characterization of the interaction of KS-Bcl-2 and PICT-1 is likely to shed light on the functions of both proteins.Kaposi''s sarcoma (KS)-associated herpesvirus (KSHV), also referred to as human herpesvirus 8 (HHV-8), is a gamma 2 herpesvirus implicated in several cancers, including KS, primary effusion lymphoma (PEL), and a subset of multicentric Castleman''s disease. Among human viruses, KSHV is most closely related to the Epstein-Barr virus (EBV), a tumorigenic gamma 1 herpesvirus known to be associated with lymphomas and nasopharyngeal carcinoma (10, 12).KSHV open reading frame 16 (orf16) encodes the KS-Bcl-2 protein, which shares sequence and functional homology with the Bcl-2 family (9, 31). Members of the Bcl-2 family are defined by the presence of up to four conserved domains known as the Bcl-2 homology (BH) domains. Several members also possess a carboxy-terminal transmembrane domain that mediates their association with intracellular membranes, such as the endoplasmic reticulum or mitochondria. Bcl-2 proteins are thought to serve primarily as cell death agonists or antagonists that integrate diverse survival and death signals, which are generated outside and within the cell (15, 37), yet Bcl-2 proteins also modulate cell cycle checkpoints, DNA repair/recombination pathways, calcium homeostasis, and cellular bioenergetics.All gammaherpesviruses encode Bcl-2 proteins that generally share 20 to 30% homology with one another and with their cellular counterparts (8, 11). The conservation of Bcl-2 homologues in these viruses indicates their importance for viral infection, with an evolutionarily conserved function of unknown nature. KS-Bcl-2, like most herpesvirus homologues of Bcl-2, contains a transmembrane domain and demonstrates conservation of sequences in both BH1 and BH2 but has only a low degree of homology with other regions of cellular Bcl-2 (18, 22). Still, KS-Bcl-2 shares 3-dimensional structural conservation with Bcl-2 family members and includes the conserved BH3 binding groove and a hydrophobic membrane anchor domain that also contains a mitochondrial outer membrane targeting signal (18). The BH3 binding cleft of KS-Bcl-2 binds with high affinity to peptides encoding BH3 domains present on the proapoptotic proteins Noxa, Bik, PUMA, Bak, Bax, Bid, Bim, and, to a much lesser extent, Bad (13, 18, 22). Based on these characteristics, KS-Bcl-2 has been suggested to have the closest resemblance to the cellular Bcl-2 family member Mcl-1 (13).Previous studies have demonstrated that KS-Bcl-2 protects various cell types from apoptosis mediated by the expression of BAX, tBid, or Bim through Sindbis virus infection or by ectopic expression of KSHV-cyclin-CDK6 (9, 13, 25, 31). However, unlike the cellular Bcl-2, KS-Bcl-2 is not a substrate for KSHV-cyclin-CDK6 phosphorylation (25) and cannot be converted into a proapoptotic protein via caspase cleavage (3). KS-Bcl-2 is able to form a stable complex with the cellular protein Aven, which binds Apaf-1 and is known as a regulator of caspase 9 and ataxia-telangiectasia (ATM) activation (7, 16). Like the cellular and other virus-encoded Bcl-2 proteins, KS-Bcl-2 binds Beclin and disrupts its lysosomal degradation pathway of autophagy (21, 29). However, since KS-Bcl-2 lacks the nonstructured loop located between the BH4 and BH3 domains, its binding to BH3-containing proapoptotic proteins and to the BH3-containing proautophagy protein Beclin is not modulated by phosphorylation (38).KS-Bcl-2 is transcribed during lytic virus infection (30, 31). Thus, inhibition of apoptosis and autophagy by KS-Bcl-2 may provide an attractive mechanism for prolonging the life span of KSHV-infected cells, which in turn enables increased virus production or establishment of latency. Whether the function of KS-Bcl-2 is necessary for KSHV-mediated oncogenesis is still unknown. Nevertheless, the KS-Bcl-2 protein is expressed in late-stage KS lesions but has not been detected in latent or in lytic KSHV-infected PEL cells (39).To explore the role of KS-Bcl-2 in cell signaling, we searched for its potential cellular-protein partners. In the present study, we describe a novel interaction between KS-Bcl-2 and the protein interacting with carboxyl terminus 1 (PICT-1) cellular protein, encoded by a candidate tumor suppressor gene, GLTSCR2. We show that this interaction specifically targets KS-Bcl-2 to the nucleolus and decreases its antiapoptotic activity.(Portions of this work were submitted to Bar Ilan Univeristy, Ramat Gan, Israel, by I. Kalt and T. Borodianskiy-Shteinberg in partial fulfillment of the requirements for the degree of Doctor of Philosophy.)